March 28, 2025 07:00 AM EDTUpdated March 29, 12:45 AM
Peer Review

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

Kathy Wong

Editor

→ Af­ter a 6-year run, CRISPR Ther­a­peu­tics COO Ju­lianne Bruno is step­ping out the door to pur­sue oth­er op­por­tu­ni­ties. Bruno’s de­par­ture …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times